'LdI-Cholesterol-Lowering Cell Extract And Food Supplement' in Patent Application Approval Process (USPTO 20210275601)

摘要

2021 SEP 29 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - A patent application by the inventors Mastroleo, Felice (Vorselaar, BE); Suters, Robertus Christiaan Josephus (Ros-malen, NL); Wattiez, Ruddy (Sirault, BE), filed on May 7, 2021, was made available online on September 9, 2021, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to ezCol B.V. (Rosmalen, Netherlands). The following quote was obtained by the news editors from the background information supplied by the inventors: "Cardiovascular disease is caused by a number of synergistic factors, the most important being a too high blood cholesterol level. Cholesterol is an essential building block for animal and human cells, since it is a component of cell membranes. Human cells can synthesize their own cholesterol, but cholesterol is also assimilated from food. Both processes play an important part in cholesterol metabolism. "Apart from its essential biological role as a building block for cellular membranes, cholesterol also has negative effects on human health, as a cause of cardiovascular disease (such as, for instance, myocar-dial infarction, stroke, and peripheral vascular disease), more specifically in relation to the occurrence of atherosclerotic lesions in the blood vessel wall. An elevated plasma cholesterol level is the most important predictive risk factor for the occurrence of cardiovascular disease and atherosclerosis.